Cargando…

Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration

BACKGROUND: Photodynamic therapy (PDT) is known to occlude choroidal neovascularisation selectively, and there have been several reports on its adverse effects on the normal choroid and retinal pigment epithelium, resulting in decreased vision. METHODS: This retrospective interventional case series...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Min Ho, Chung, Yoo-Ri, Song, Ji Hun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901101/ https://www.ncbi.nlm.nih.gov/pubmed/33618709 http://dx.doi.org/10.1186/s12886-021-01867-w

Ejemplares similares

The Effect of Topical Bromfenac on Intraretinal and Subretinal Fluid in Neovascular Age-Related Macular Degeneration
por: Abdolrahimzadeh, Solmaz, et al.
Publicado: (2020)

Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
por: Yildiz, Dilan, et al.
Publicado: (2021)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
por: Williams, Patrick D, et al.
Publicado: (2012)

Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration
por: Roberts, Philipp K., et al.
Publicado: (2022)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?
por: Desmettre, Thomas, et al.
Publicado: (2023)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Juliano, Joseph, et al.
Publicado: (2021)

Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration
por: Little, Karis, et al.
Publicado: (2020)

Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
por: Kim, Hyun Woong, et al.
Publicado: (2011)

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study
por: Alex, Divya, et al.
Publicado: (2021)

Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives
por: Tenbrock, Louis, et al.
Publicado: (2021)

Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia
por: Rishi, Pukhraj, et al.
Publicado: (2009)

Erratum in: Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
Publicado: (2021)

Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients
por: Kim, Kyung Tae, et al.
Publicado: (2021)

Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment
por: Cho, Han Joo, et al.
Publicado: (2022)

Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis
por: Roberts, Philipp Ken, et al.
Publicado: (2021)

APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway
por: Sun, Yiwen, et al.
Publicado: (2020)

A Method for En Face OCT Imaging of Subretinal Fluid in Age-Related Macular Degeneration
por: Mohammad, Fatimah, et al.
Publicado: (2014)

Effect of the Duration of Intraretinal or Subretinal Fluid on the Response to Treatment in Undertreated Age-Related Macular Degeneration
por: Yoshida, Izumi, et al.
Publicado: (2020)

Photodynamic Therapy for Subretinal New Vessels
por: Lee, Sung Chul, et al.
Publicado: (2007)

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011)

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

Chorioretinal thickness and retinal pigment epithelial degeneration of fellow eyes in patients with unilateral neovascular age-related macular degeneration with subretinal drusenoid deposits
por: Kang, Dongwan, et al.
Publicado: (2022)

Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD)
por: Sharma, Ashish, et al.
Publicado: (2020)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma
por: Morris, Rodney J, et al.
Publicado: (2011)

Low-fluence photodynamic therapy for early onset choroidal neovascular membrane following laser in situ keratomileusis
por: Manayath, George J, et al.
Publicado: (2012)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Brolucizumab for Choroidal Neovascular Membrane with Pigment Epithelial Tear and Subretinal Fluid
por: Bilgic, Alper, et al.
Publicado: (2021)

Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration
por: Avcı, Remzi, et al.
Publicado: (2021)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
por: Ahmadieh, Hamid, et al.
Publicado: (2007)

Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration
por: Tsuchihashi, Takashi, et al.
Publicado: (2013)

Imaging Histology Correlations of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration
por: Berlin, Andreas, et al.
Publicado: (2023)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Subretinal alteplase injections in massive subretinal hemorrhage due to age-related macular degeneration: A case report series
por: Ochinciuc, Radu, et al.
Publicado: (2020)

Optical Coherence Tomography Angiography of Macular Telangiectasia Type 2 with Associated Subretinal Neovascular Membrane
por: Villegas, Victor M., et al.
Publicado: (2017)

Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g332uhmi0m8jeim634a4bov7ra